PlumX Metrics
Embed PlumX Metrics

Biomimetic artificial cells to model the effect of membrane asymmetry on chemoresistance

Chemical Communications, ISSN: 1364-548X, Vol: 57, Issue: 53, Page: 6534-6537
2021
  • 15
    Citations
  • 0
    Usage
  • 26
    Captures
  • 3
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Most Recent News

New cancer treatments can be tested in artificial cells on tiny chips the size of a postage stamp

It usually takes 10 to 15 years to develop a new drug, and they cost around US$2.6 billion each. Because it's difficult to predict how a drug candidate will interact with human cells, many drugs never pass clinical trials. Testing new drugs on human cells is expensive and complicated, so it is difficult to do early in the development of a drug.

Article Description

We present a microfluidic platform that enables the formation of bespoke asymmetric droplet interface bilayers (DIBs) as artificial cell models from naturally-derived lipids. We use them to perform pharmacokinetic assays to quantify how lipid asymmetry affects the permeability of the chemotherapy drug doxorubicin. Previous attempts to model bilayer asymmetry with DIBs have relied on the use of synthetic lipids to achieve asymmetry. Use of natural lipids serves to increase the biomimetic nature of these artificial cells, showcasing the next step towards forming a true artificial cell membranein vitro. Here we use our microfluidic platform to form biomimetic, asymmetric and symmetric DIBs, with their asymmetry quantified through their life-mimicking degree of curvature. We subsequently examine permeability of these membranes to doxorubicin, and reveal measurable differences in its pharmacokinetics induced by membrane asymmetry, highlighting another factor that potentially contributes to chemoresistance in some forms of cancer.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know